Full Press Release Details
Biotechnology Holdings to Present at Two Investor Conferences
to Present August 20 at Investor Summit Summer 2024 Virtual Conference;
and September 9-11 at H.C. Wainwright 26th Annual Global Investment Conference-
CALIF., August 15, 2024 - LIXTE Biotechnology
Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical
company, today announced it will be presenting at two investor conferences:
van der Baan, CEO of LIXTE, will present an overview of the Company's clinical trials with LB-100, its proprietary compound focused
on enhancing chemotherapy and immunotherapy treatments as cancer therapies. Proof-of-concept clinical
trials are currently in progress for colorectal, ovarian and sarcoma cancers, including trials funded by GSK and Roche.
LIXTE Biotechnology Holdings
Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing
and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated
in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com),
LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology - activation lethality -
that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept
clinical trials are currently in progress for colorectal, ovarian and sarcoma cancers. Additional information about LIXTE can be found
more information about LIXTE, Contact:
General Phone: (631) 830-7092
Phone: (888) 289-5533
Inc. Investor Relations
Pondel: (310) 279-5965
Berman: (310) 279-5962